Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 154 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: METERED-DOSE INHALER (MDI) Clear all
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
View directory record Official record
Conditions
Persistent Asthma
Interventions
Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

NCT01479621
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
129
States / cities
Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 14, 2026, 4:50 AM EDT
Withdrawn Phase 2 Interventional

Repeated High-dose Inhaled Corticosteroids for Asthma

NCT00695604
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Fluticasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 14, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

NCT01396278
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Fluticasone propionate, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
37
States / cities
Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

NCT00667992
View directory record Official record
Conditions
Asthma
Interventions
Budesonide HFA, Budesonide CFC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

BI 671800 ED in Steroid-naive Asthmatic Patients

NCT01092143
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Fluticasone propionate placebo, Fluticasone propionate, BI 671800 Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Tucson, Arizona • Cypress, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 14, 2026, 4:50 AM EDT
Completed No phase listed Observational

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

NCT02135718
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA inhaler, Placebo Inhalation Aerosol (MDI)
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Huntington Beach, California • Newport Beach, California • Vista, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

NCT03879837
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate pressurized metered dose inhaler, Flovent HFA pressurized metered dose inhaler, Placebo pressurized metered dose inhaler
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Teach-to-Goal Education vs. Brief Education for Children

NCT04373499
View directory record Official record
Conditions
Asthma, Bronchospasm, Shortness of Breath
Interventions
Virtual Teach to Goal, Brief Intervention
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
5 Years to 10 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02447575
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
Education on Use of MDI
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)

NCT01426581
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Teach-To-Goal, Brief Intervention
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 14, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

NCT01397201
View directory record Official record
Conditions
Asthma
Interventions
Placebo, BI 54903, Fluticasone propionate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 14, 2026, 4:50 AM EDT
Not listed Phase 1 Interventional

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

NCT06271408
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer
Drug · Device
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

NCT00393991
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 14, 2026, 4:50 AM EDT
Not listed Early Phase 1 Interventional

Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety

NCT06656806
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Measure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD, Determine the presence and concentration of CBD in subject's plasma with inhaled CBD
Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 14, 2026, 4:50 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

NCT01737892
View directory record Official record
Conditions
Asthma
Interventions
Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation, Arm C-Epinephrine Inhalation Aerosol CFC
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers

NCT01143051
View directory record Official record
Conditions
Asthma
Interventions
epinephrine inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma

NCT00174746
View directory record Official record
Conditions
Asthma
Interventions
AVE2635A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

NCT02268396
View directory record Official record
Conditions
COPD
Interventions
Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

NCT04600505
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Treatment A, Treatment B, Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 14, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

NCT03170232
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 76 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 14, 2026, 4:50 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate

NCT07664527
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

NCT01424813
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 14, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

NCT03084718
View directory record Official record
Conditions
Asthma
Interventions
CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
134
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 14, 2026, 4:50 AM EDT